Happiness and Multiple Sclerosis

Tandem bike a great equalizer for cyclists with different fitness levels

Phase IV Tysabri data #MS Research # MSBlog Effect of Tysabri

Mitoxantrone Study: Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in WorseningMultiple Sclerosis) study.

Patient taking Novartis MS pill developed rare disease


Could Sleep Deprivation Aggravate Multiple Sclerosis?
 ABC News
Sleep Doubles Growth Of Brain Repair Cells. This explains why multiple sclerosis, an autoimmune disease that destroys myelin and kills oligodendrocytes, is so devastating. Hardened scars in the brain are the classic feature in the more than two million victims of the disease. Scientists at the University of Wisconsin-Madison (UoW) have discovered another reason why sleep is great! Resting boosts the growth of special cells — called oligodendrocytes — that repair the brain when it is injured, according to new findings reported in the Journal of Neuroscience.

High risk of cardiovascular diseases after diagnosis of multiple sclerosis
We recommend careful surveillance and preventive CVDs measures among MS patients, particularly among the women.

CAMPATH (Alemtuzumab) improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis 
Alemtuzumab was associated with a greater chance of improved contrast sensitivity in patients with RRMS and may delay the worsening of visual function.


Migraine sufferers prone to poor blood flow

Migraines Linked to Structure of Brain Arteries

Longitudinal Change in Physical Activity & Its Correlates in Relapsing-Remitting Multiple Sclerosis

Retinal periphlebitis is associated with multiple sclerosis severity

Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab (TYSABRI)

Protein kinase C polymorphisms and vitamin D levels in multiple sclerosis

Labor induction and augmentation in women with multiple sclerosis

CLICK ON "READ MORE" BELOW FOR 538 MORE STUDIES & ARTICLES WE   POSTED IN SEPTEMBER                                                                                                   


Are there Epstein-Barr virus seronegative patients with multiple sclerosis?

Renal deterioration in multiple sclerosis patients with neurovesical dysfunction

Relating health-related Quality of Life to disability progression in multiple sclerosis, using the 5-level EQ-5D

Natalizumab-induced autoimmune hepatitis in a patient with multiple sclerosis

CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions

MRI characteristics of familial and sporadic multiple sclerosis patients

Rare MEFV variants are not associated with risk to develop multiple sclerosis and severity of disease

Common genetic variants in the plasminogen activation pathway are not associated with multiple sclerosis

Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis

Studies in Experimental Autoimmune Encephalomyelitis Do Not Support Developmental Bisphenol A Exposure as an Environmental Factor in Increasing Multiple Sclerosis Risk

Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia

Natalizumab inhibits the expression of human endogenous retroviruses of the W family in multiple sclerosis patients: a longitudinal cohort study


Research and Markets: Relapsing Remitting Multiple Sclerosis ...

BURLINGTON, Mass., Sept. 3, 2013 /PRNewswire/ --  more than half of surveyed neurologists consider Biogen Idec's Tecfidera to be a breakthrough in the treatment of multiple sclerosis (MS), slightly greater than those who feel the same about Novartis's Gilenya and nearly twice as many as for Genzyme's Aubagio. 

Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis

Symptom overlap in anxiety and multiple sclerosis

Cerebral white matter blood flow and energy metabolism in multiple sclerosis
Our results suggest that in MS patients there is no relationship between reduced CBF in NAWM and impaired axonal mitochondrial metabolism or astrocytic PCr metabolism.

Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation

Assessing interactions between HLA-DRB1*15 and infectious mononucleosis on the risk of multiple sclerosis

Perceived and actual arm performance in multiple sclerosis: relationship with clinical tests according to hand dominance
This study aimed to determine the relation between real-life arm performance and clinical tests in MS.  Real-life arm performance is decreased in wheelchair-bound MS patients and can be best predicted by measures on ‘body functions & structures’ level and fine motor control.

Retinal nerve fiber layer thickness in benign multiple sclerosis

International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions

Pediatric onset multiple sclerosis: McDonald criteria 2010 and the contribution of spinal cord MRI

Application of the McDonald 2010 criteria for the diagnosis of multiple sclerosis in an Argentinean cohort of patients with clinically isolated syndromes

Childhood body mass index and multiple sclerosis risk: a long-term cohort study
Obesity in late adolescence has been associated with an increased risk of multiple sclerosis (MS); however, it is not known if body size in childhood is associated with MS risk.  Having a high BMI in early life is a risk factor for MS, but the mechanisms underlying the association remain to be elucidated.

A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica)
Definite diagnosis of inflammatory demyelinating disease (multiple sclerosis (MS) and neuromyelitis optica (NMO)) may require time, but early treatment offers the opportunity to maximize patient outcomes.

Half of new MS patients may soon get Biogen’s Tecfidera
Boston-based financial services group Cowen Group Inc. said Friday morning that based on patient data, Biogen Idec Inc.’s new drug, Tecfidera, may soon be getting more than half of all new multiple sclerosis patients. The Weston, Mass. biotech launched Tecfidera in March and has managed to outdo already-high expectations ever since. During its first three months on the market, the drug accounted for more than 10 percent of the Weston, Mass.-based drug company’s second-quarter revenues of $1.7 billion, which was up 21 percent year-over-year.



Therapeutic potential of cannabinoid medicines.
Cannabis was extensively used as a medicine throughout the developed world in the nineteenth century but went into decline early in the twentieth century ahead of its emergence as the most widely used illicit recreational drug later that century. This paper will then go on to review clinical research exploring the potential of cannabinoid medicines in the following indications: symptomatic relief in multiple sclerosis, chronic neuropathic pain, intractable nausea and vomiting, loss of appetite and weight in the context of cancer or AIDS, psychosis, epilepsy, addiction, and metabolic disorders.

Post-Tysabri (natalizumab) clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up.
There is an urgent need to identify the best strategies to prevent the loss of natalizumab (N) beneficial effects after its suspension. The objective is to evaluate the clinical and radiological disease activity and to test the efficacy of immunomodulatory/immunosuppressive drugs (IT) after N suspension.

Quality of life and employment in persons with multiple sclerosis.
Results of the study emphasize the need for the provision of quality vocational services to persons with MS. Issues such as quality vocational services, timeliness, and the importance of continued work  are discussed.

The experience of being grounded: a phenomenological study of living with a wheelchair.
The purpose of this existential-phenomenological study was to investigate the experience of being in a wheelchair. It was a prelude to a pilot study examining the effect of "seated" Tai Chi.  The accommodations from the ADA Act have greatly facilitated the independence for those who are disabled, yet many obstacles remain.

 Epstein-Barr virus in oral shedding of children with multiple sclerosis

Notre Dame Men's Tennis Set To Host "Smash MS" Clinic Saturday

Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study

Tour de South Shore ride to benefit Alzheiemer's, MS research

Monoclonal antibodies in targeted therapy.

What sample sizes for reliability and validity studies in neurology?

Improved operator agreement and efficiency using the minimum area contour change method for delineation of hyperintense multiple sclerosis lesions on FLAIR MRI.

A Novel pH-Sensitive Interferon-β (INF-β) Oral Delivery System for Application in Multiple Sclerosis.

Neuromyelitis optica: atipic clinic presentation.

Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development.

Connexin 43 astrocytopathy linked to rapidly progressive multiple sclerosis and neuromyelitis optica.
Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?
Matrix metalloproteinases and their pathological upregulation in multiple sclerosis: an overview.

Meta-Analysis of the Correlation Between Chronic Cerebrospinal Venous Insufficiency and Multiple Sclerosis.
To determine whether a correlation exists between chronic cerebrospinal venous insufficiency (CCSVI) and multiple sclerosis (MS).

Dry Eyes Tied to Lower Pain Threshold
Women with dry eye disease had a greater overall sensitivity to pain and lower pain tolerance compared with women without the condition, researchers found.




Cognitive functions in multiple sclerosis: impact of gray matter integrity.
Our aim was to investigate the impact of gray matter (GM) integrity on cognitive performance in multiple sclerosis (MS), and its relationship with white matter (WM) integrity and presence of lesions.  GM and WM integrity of specific networks influences cognitive performance in MS. However, GM damage assessed by DTI only adds a small increment to the explained variance by WM in predicting cognitive functioning.

(CCVI) Chronic cerebrospinal venous insufficiency--pathophysiology and treament
Multiple sclerosis (sclerosis multiplex--SM) is a chronic nervous sytem disease, which through formation of demyenilisation focus in the central nervous system leads to deterioration of its various functions. In the consequence it may cause invalidity of patient.


 Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis


Symptom overlap in anxiety and multiple sclerosis

Cerebral white matter blood flow and energy metabolism in multiple sclerosis

Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation

Assessing interactions between HLA-DRB1*15 and infectious mononucleosis on the risk of multiple sclerosis

Perceived and actual arm performance in multiple sclerosis: relationship with clinical tests according to hand dominance

Retinal nerve fiber layer thickness in benign multiple sclerosis

International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system

Pediatric onset multiple sclerosis: McDonald criteria 2010 and the contribution of spinal cord MRI

Application of the McDonald 2010 criteria for the diagnosis of multiple sclerosis in an Argentinean cohort of patients with clinically isolated syndromes

Childhood body mass index and multiple sclerosis risk: a long-term cohort study
 
High risk of cardiovascular diseases after diagnosis of multiple sclerosis


Brain Changes May Explain Stroke Risk In Migraine Sufferers

Some people who get migraines do have a slightly higher risk of stroke. And some of the brain changes identified in the study look like mini strokes. "On the MRI migraines look like very tiny strokes," Lipton tells Shots. But the people aren't having any stroke symptoms. Still, Lipton is convinced that the process is the same. "We now know it's a risk factor for these very small silent strokes,"


Migraine and structural changes in the brain: A systematic review and meta-analysis

Migraine prevalence, socioeconomic status, and social causation

Sunbathing more effective than vitamin D in preventing multiple sclerosis
A little ray of sunshine can help combat fatigue and depression and decrease the risk of multiple sclerosis, according to new findings. GETTING a regular dose of sunshine is much more effective than vitamin D at combating fatigue and depression. STUDY: Participants also reported on the length of time they spent sunbathing. It emerged that those who spent longer in the sun suffered less from fatigue and depression.

MS study targets damage affecting nerves
Dr Veronique Miron, MRC for Regenerative Medicine at the University of Edinburgh, explains that "In multiple sclerosis patients, the protective layer surrounding ..

A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica)

2010 McDonald criteria in a pediatric cohort: is positivity at onset associated with a more aggressive multiple sclerosis course?

A case of hereditary diffuse leukoencephalopathy with axonal spheroids caused by a de novo mutation in CSF1R masquerading as primary progressive multiple sclerosis

Gene expression changes underlying cortical pathology: clues to understanding neurological disability in multiple sclerosis
 
Higher Relative Risk for Multiple Sclerosis in a Pediatric and Adolescent Diabetes Population: Analysis From DPV Data Base


Indian Ranch to Host Concert To Benefit CFMS Foundation

Assessment of the influence of rehabilitation in patients treated in a hospital rehabilitation ward due to consequences of neurological diseases

Epidemiology in multiple sclerosis: a pilgrim's progress.

Dr. Jill Conway

The cost of medication and the cost of treatment are not the same thing for multiple sclerosis.

Charlotte doctor commits her career to treating multiple sclerosis
Dr. Jill Conway, director of the Multiple Sclerosis Cenjter at Carolinas Medical Center, enjoys working in a field with so many medical advances and one that ...

Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome and healthy control participants: study protocol for an exploratory randomized double- blind placebo-controlled trial.

European Commission Approves Genzyme's Once-Daily, Oral Aubagio...
Wall Street Journal

Review series on immune responses in neurodegenerative diseases: Oligodendrocyte-microglia cross-talk in the CNS.

Predictors of executive complaints and executive deficits in multiple sclerosis.
Among the study variables, depression was the strongest predictor of executive complaints. A high degree of neurological disability was the strongest predictor for executive deficit, measured by neuropsychological tests.

A comparison of sagittal short T1 inversion recovery and T2-weighted FSE sequences for detection of multiple sclerosis spinal cord lesions.
Multiple sclerosis (MS) is the most common disabling CNS disease of young adults.  Short T1 inversion recovery sequence imaging not only significantly improves detection of MS lesions within the spinal cord, but also provides better contrast and conspicuity of visible lesions, creating a more confident diagnostic measure of MS extent and progression. Short T1 inversion recovery sequences of the spinal cord should be routinely obtained during initial and routine follow-up of MS.

Changes in expression of the antioxidant enzyme SOD3 occur upon differentiation of human bone marrow-derived mesenchymal stem cells in vitro.

A standardized motor imagery introduction program (MIIP) for neuro-rehabilitation: development and evaluation.

The quality of primary health care for chronically ill patients: a cross-sectional study.
The areas that the participants gave the highest ratings to are subjective and objective examinations, kindness and willingness to help. The strongest correlations between high assessments of the quality of care provided for chronically ill patients at primary care clinics were observed in the following variables: gender, age, level of education, frequency of visits, therapy conducted by a doctor at a specialist clinic, arterial hypertension, COPD and/or myocardial infarction.

Pathophysiology of the brain extracellular matrix: a new target for remyelination.

IL7RA haplotype-associated alterations in cellular immune function and gene expression patterns in multiple sclerosis.

Endogenous retroviruses and multiple sclerosis--new pieces to the puzzle.

Assessment of the influence of rehabilitation in patients treated in a hospital rehabilitation ward due to consequences of neurological diseases.

Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications.

Survival and predictors of mortality in systemic sclerosis associated pulmonary arterial hypertension: Outcomes from the PHAROS registry.


Obama administration will not block state marijuana laws, if distribution is regulated - The Washington Post
he Obama administration said Thursday that it would not challenge laws legalizing marijuana in Colorado and Washington State as long as those states maintain strict rules involving the sale and distribution of the drug.
In a memo to US Attorneys in all 50 States, Deputy Attorney General James M. Cole said the Justice Department is “committed to using its limited investigative and prosecutorial resources to address the most significant threats in the most effective, consistent and rational way.” He stressed that marijuana remains illegal under federal law.

The effect of Prozac (fluoxetine) on progression in progressive multiple sclerosis: a double-blind, randomized, placebo-controlled trial.
ISRN Neurol. 2013 Jul 29;2013:370943. doi: 10.1155/2013/370943.
Department of Neurology, University Medical Center Groningen, University of Groningen, Postbus 30.001, 9700 RB Groningen, The Netherlands ; Department of Neurology, Rijnstate Hospital, Postbus 9555, 6800 TA Arnhem, The Netherlands.


Medication withdrawal may be an option for a select group of patients in relapsing-remitting multiple sclerosis.
This article describes the clinical and radiological evolution of a stable group of patients with relapsing-remitting multiple sclerosis that had their disease-modifying therapy (DMT) withdrawn. Withdrawal, however, should not be viewed as simply the suspension of treatment because these patients should be evaluated periodically, and the immunomodulators should be readily reintroduced if new attacks occur. Nonetheless, medication withdrawal is an option for a select group of patients.

Antiparasitic antibodies occur with similar frequency in patients with clinically established multiple sclerosis with or without oligoclonal bands in the cerebrospinal fluid.

Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis.
Department of Neurology, University of California, San Francisco, CA, USA.
Clinically isolated syndrome (CIS) is a central nervous system demyelinating event isolated in time that is compatible with the possible future development of multiple sclerosis (MS). Early risk stratification for conversion to MS helps with treatment decisions. Magnetic resonance imaging (MRI) is currently the most useful tool to evaluate risk.

Walking execution is not affected by divided attention in patients with multiple sclerosis with no disability, but there is a motor planning impairment.
Conclusion: MS patients with no disability did not show any influence of divided attention on walking execution. However, motor planning was overestimated as compared with real walking.

MicroRNAs as Novel Regulators of Neuroinflammation.

The effect of vitamin a supplementation on biochemical parameters in multiple sclerosis patients.

A&W's Cruisin' for a Cause Raises $5 Million Over 5 Years
Wall Street Journal: Cruisin' for a Cause (or le Rendez-vous A&W pour stopper la SP as it is known in Quebec) raised both funds and awareness of multiple sclerosis through a ...

In systemic sclerosis, anxiety and depression assessed by hospital anxiety depression scale are independently associated with disability and psychological factors.
Biomed Res Int. 2013;2013:507493. doi: 10.1155/2013/507493. Epub 2013 Jul 29.

Therapeutic Effect of Transplanted Human Wharton's Jelly Stem Cell-Derived Oligodendrocyte Progenitor Cells (hWJ-MSC-derived OPCs) in an Animal Model of Multiple Sclerosis.

Now this will Mekk you feel better!
The Samson Centre is the home of The Multiple Sclerosis Therapy Group in Guildford and is a small self-funded charity that provides physiotherapy and oxygen ...

Coping with a New Multiple Sclerosis Diagnosis
Huffington Post Canada: In her weekly column, Natalie answers your questions about caring for a family member or friend who needs extra support -- and caring for yourself as a ...

Band performs for MS
The Band of Her Majesty's Royal Marines Plymouth will perform a one-off fundraising concert for Multiple Sclerosis Auckland in September.

There is much to be learnt about the costs of multiple sclerosis in Latin America.

Multiple sclerosis is primarily a neurodegenerative disease.

Dr. Bill Code, M.D. to Present on Integrative Therapies for Brain Recovery in Multiple Sclerosis

Nutra Pharma Announces Delivery of Nyloxin(tm) to New Vitality
... biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and ...

FDA Warns of PML Case With Gilenya
MedPage Today: A patient being treated for multiple sclerosis and who had no history of using natalizumab (Tysabri) developed progressive multifocal ...

Home-based exercise program and fall-risk reduction in older adults with multiple sclerosis: phase 1 randomized controlled trial.

Sex-specific extent and severity of white matter damage in multiple sclerosis: Implications for cognitive decline.


Tecfidera’s Patient Share at Three Months Postlaunch Surpasses That for Aubagio and Gilenya At the Same Stage of Their Launches
Over the next six months, Tecfidera's patient share among DMT-treated RR-MS patients is anticipated to increase significantly to 16 percent. In fact, despite being the third oral DMT to reach the MS market, patient share for Tecfidera exceeds that for the first two oral DMTs for MS—Sanofi/Genzyme’s Aubagio (1 percent) and Novartis’s Gilenya (1 percent)—at the same stage of their respective launches. Current physician trial rate for Tecfidera (65 percent) beats that for Aubagio (33 percent) and Gilenya (53 percent).

Salt-Heavy Diets Can Lead to Autoimmune Diseases
Men's Journal
These ailments, which include multiple sclerosis, type 1 diabetes, inflammatory bowel disease, and psoriasis, result from an immune system gone haywire that ...

Prescription-Drug Coupons — No Such Thing as a Free Lunch
Visit nearly any official website for a brand-name drug available in the United States and, mixed in with links to prescribing and safety information, you'll find links to drug “coupons,” including copayment-assistance programs and monthly savings cards. Most offers are variations on “Why pay more? With the [drug] savings card, you can get [drug] for only $18 per prescription if eligible” or “Get a free 30-capsule trial of [drug] with your doctor's prescription and ask your doctor if [drug] is right for you.” Why do manufacturers offer drug coupons? Are they good for patients in the long run? Are they even legal?

Endogenous retroviruses and multiple sclerosis--new pieces to the puzzle
7thSpace Interactive (press release)
The possibility that retroviruses play a role in multiple sclerosis (MS) has long been considered; accumulating findings suggest this to be most likely in the form of ...

How Will the Obamacare Out-of-Pocket Cap Delay Affect MS Patients?
Healthline
For people with multiple sclerosis (MS) who must often pay high co-payments for health services and prescription drugs, this news comes as a crushing blow.

Opexa Therapeutics Inc awarded 50th patent for T-cell immunotherapy platform for multiple sclerosis
MENAFN.COM
Aug 28, 2013 (Menafn - M2 EQUITYBITES via COMTEX) --Biotechnology company Opexa Therapeutics Inc (nasdaqcm:OPXA) reported on Tuesday the receipt ...

Atos Tests Branded 'Farcical' After Finding Multiple Sclerosis ...
Huffington Post UK
The study looked at people with cystic fibrosis, multiple sclerosis, Parkinson's or rheumatoid arthritis who applied for Employment Support Allowance between ...

Big Sunfest cheques thrill MS societies
Canada.com
Both the Cowichan Exhibition Society and the Cowichan Valley chapter of the Multiple Sclerosis Society were the happy recipients of big cheques Thursday, ..

Non-myeloablative autologous haematopoietic stem cell transplantation
expands regulatory cells and depletes IL-17 producing mucosal-associated
invariant T cells in multiple sclerosis

Magnetic resonance monitoring of lesion evolution in multiple sclerosis
 
 Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner   

Community: Sept. 21 event to benefit MS program
Corvallis Gazette Times
The runs will benefit Oregon State's Multiple Sclerosis Exercise Program, which helps people with multiple sclerosis. Participants in the program receive free ...


Neurostimulators for the Treatment of Primary Headaches
Response rates reported in neurostimulation studies do not seem superior to those of the most effective prophylactic medications. Selection criteria for neurostimulation in headache patients are not uniform, and with few exceptions follow-up is too short to provide firm conclusions on long-term efficacy and safety, as well as costs. Notwithstanding these limitations, occipital nerve stimulation does seem to produce satisfactory improvement in chronic drug-resistant cluster headache and when it does not produce benefit, hypothalamic stimulation can be considered. Occipital nerve stimulation has been extensively investigated as a treatment of chronic migraine, but there is still some skepticism about its efficacy.[88]

Signs and symptoms of Multiple Sclerosis
Palm Beach Post
It is estimated that more than 2.1 million people worldwide are affected by multiple sclerosis (MS). Multiple sclerosis is a chronic, often disabling disease that ...

Atos Tests Branded 'Farcical' After Finding Multiple Sclerosis ...
Huffington Post UK
People with crippling illnesses like cystic fibrosis and multiple sclerosis are being found fit for ... The study looked at people with multiple sclerosis, Parkinson's or ...

 Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner
   Celia Oreja-Guevara, Heinz Wiendl, Bernd C. Kieseier, and Laura Airas
   Therapeutic Advances in Neurological Disorders. published 27 August
   2013, 10.1177/1756285613501575
   http://tan.sagepub.com/cgi/content/abstract/1756285613501575v1?ct=ct

Natural killer cells and their receptors in multiple sclerosis
   Gurman Kaur, John Trowsdale, and Lars Fugger
   Brain. 2013;  136(9): p. 2657-2676
   http://brain.oxfordjournals.org/cgi/content/abstract/136/9/2657?ct=ct

T-cell homeostasis in pediatric multiple sclerosis: Old cells in young patients
   Bettina Balint, Jurgen Haas, Alexander Schwarz, Sven Jarius, Alexandra
   Furwentsches, Kathrin Engelhardt, Cornelia Bussmann, Friedrich Ebinger,
   Benedikt Fritzsching, Friedemann Paul, Ulrich Seidel, Stefan Vlaho,
   Peter Huppke, Jutta Gartner, and Brigitte Wildemann
   Neurology. 2013;  81(9): p. 784-792
   http://www.neurology.org/cgi/content/abstract/81/9/784?ct=ct

Epidemiology in multiple sclerosis: a pilgrim's progress
   John F. Kurtzke
   Brain. 2013;  136(9): p. 2904-2917
   http://brain.oxfordjournals.org/cgi/content/abstract/136/9/2904?ct=ct

Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis
   Sofia V. Abrahamsson, Daniela F. Angelini, Amy N. Dubinsky, Esther
   Morel, Unsong Oh, Joanne L. Jones, Daniele Carassiti, Richard Reynolds,
   Marco Salvetti, Peter A. Calabresi, Alasdair J. Coles, Luca Battistini,
   Roland Martin, Richard K. Burt, and Paolo A. Muraro
   Brain. 2013;  136(9): p. 2888-2903
   http://brain.oxfordjournals.org/cgi/content/abstract/136/9/2888?ct=ct

Magnetic resonance monitoring of lesion evolution in multiple sclerosis
   Alex Rovira, Cristina Auger, and Juli Alonso
   Therapeutic Advances in Neurological Disorders. 2013;  6(5): p. 298-310
   http://tan.sagepub.com/cgi/content/abstract/6/5/298?ct=ct

The Multiple Sclerosis Association of America Launches New ...
Sacramento Bee
CHERRY HILL, N.J., Aug. 27, 2013 -- /PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA) is pleased to announce new website additions ...

Dresher Jeweler Holding Multiple Sclerosis Fundraiser
Patch.com
28, Lester Martin Jewelers, at 1650 Limekiln Pike in Dresher, will donate a portion of their proceeds to the Multiple Sclerosis Society of Greater Philadelphia.

Sobell changing gears on fundraiser
Lompoc Record
All money raised will be donated to the National Multiple Sclerosis Society. Registration fee is $50 and includes the run/ride, rest stops, support and gear and the ...

 Use of a biomarker in exposure-response analysis to support dose selection for fingolimod.

Patient-related factors may affect the outcome of neuropsychological rehabilitation in multiple sclerosis.
Patient-related factors affected rehabilitation outcome, whereas illness- and intervention-related factors did not. The results showed that especially MS patients with male gender and more severe attentional deficits benefitted from the intervention (attention retraining, teaching compensatory strategies, psychoeducation, psychological support, and homework assignments).

Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy.

Prolonged and symptomatic bradycardia following a single dose of GILENYA


CLINICAL TRIAL: Investigators Recruiting For Study of Lower Dose of Gilenya Versus Copaxone In MS

 Information on Current and Completed Pregnancy Registries for MS Therapies

(VIDEO) A Summer Spent At MS Center Offers Insight Into Mom's Battle

T-cell homeostasis in pediatric multiple sclerosis: Old cells in young patients

Premature immune senescence in children with MS: Too young to go steady

Glatiramer acetate–induced acute hepatotoxicity in an adolescent with MS

Cerebrospinal fluid derived immunoglobulin G of different multiple sclerosis patients share mutated sequences in complementarity determining regions.

The impact of diagnostic criteria for neuromyelitis optica in patients with MS: a 10-year follow-up of the South Atlantic Project.

Application and a proposed modification of the 2010 McDonald criteria for the diagnosis of multiple sclerosis in a Canadian cohort of patients with clinically isolated syndromes.

Paroxysmal ataxia and dysarthria in multiple sclerosis.

Evidence against the Involvement of Chronic Cerebrospinal Venous Abnormalities in Multiple Sclerosis. A Case-Control Study.

Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials.

Genetic variation near IRF8 is associated with serologic and cytokine profiles in systemic lupus erythematosus and multiple sclerosis.

Health plan utilization and costs of specialty drugs within Multiple Sclerosis


Depression: Can a Coach Help?
Adding old-fashioned technology -- the telephone -- to a Web-based  intervention for depression improved adherence to the intervention, but there was no symptom benefit. Compared with those who did not receive telephone coaching to help navigate the depression treatment software, coached patients had significantly more login days (P=0.01) and were likely to continue to use the software for longer periods according to David Mohr, PhD, of Northwestern University Feinberg School of Medicine in Chicago, Ill.,

Pilates for people with multiple sclerosis who use a wheelchair: feasibility, efficacy and participant experiences.
Pilates appears to be efficacious in improving sitting stability and posture and decreasing pain and was also well tolerated by wheelchair users with MS. Further mixed methods studies are warranted. Implications for Rehabilitation Group-based core stability exercise or Pilates for people with MS who use wheelchair is a feasible and safe way of exercising for this patient group. Pilates exercises for people moderately to severely affected by MS resulted in a decrease in back and shoulder pain and improvement in sitting balance. Future appropriately powered randomised controlled studies into Pilates for people with MS reliant on wheelchair are warranted.

AUBAGIO (Teriflunomide) in relapsing multiple sclerosis: therapeutic utility
Therapeutic Advances in Chronic Dis

Surgery and Risk for Multiple Sclerosis: A Systematic Review and Meta-analysis of Case-Control Studies

Abstract-Background: Although the precise etiology of multiple sclerosis is largely unknown, there is some speculation that a prior history of surgery may be associated with the subsequent risk for developing the disease. Therefore, we aimed to examine surgery as a risk factor for the diagnosis of multiple sclerosis.
ease. 2013

The effects of pilates on balance, mobility and strength in patients with multiple sclerosis. NeuroRehabilitation. 2013  [Epub ahead of print]

Seizure Disorders Enter Medical Marijuana Debate

Evaluation of plaque detection and optimum time of enhancement in acute attack multiple sclerosis after contrast injection

Parasite Infections in Multiple Sclerosis Modulate Immune Responses through a Retinoic Acid-Dependent Pathway

Clinic speak: an holistic approach to MS version 3.1

Concomitant amyotrophic lateral sclerosis and paraclinical laboratory features of multiple sclerosis: coincidence or causal relationship?

Relapsing-remitting multiple sclerosis and chronic idiopathic neutropenia: a challenging combination



High dose thiamine improves fatigue in multiple sclerosis
The majority of the patients with multiple sclerosis (MS) experience  fatigue. Some observations indicate that fatigue and related manifestations concomitant with MS could be associated with an intracellular mild thiamine deficiency. Although blood thiamine and thiamine pyrophosphate levels were within normal limit in all the patients, high-dose thiamine therapy administered orally or parenterally led to an appreciable improvement of the fatigue.The administration of large quantities of thiamine was effective in reversing the fatigue in MS, suggesting that the abnormalities in thiamine-dependent processes could be overcome by diffusion-mediated transport at supranormal thiamine concentrations.


The Physiological Changes of MSMultiple sclerosis attacks the body’s central nervous system and can cause quite severe reactions and symptoms if not properly treated. Here are a few physiological changes of multiple sclerosis (MS) and the effect that they have on your body. Some of the most well-known symptoms of MS can include muscle weakness, vision trouble, coordination problems, memory issues and sensations of numbness. However, you might not realize just how this condition affects the body. It affects the brain and nervous system and each patient’s symptoms can be less or more severe than the next, depending on their individual condition.

A new study appearing in the latest issue of STEM CELLS Translational Medicine is the first to demonstrate that, in fact, adipose-derived stem cells donated by older people are less effective than cells from their younger counterparts.

Biogen Idec, Elan facing suits over Tysabri side effects-Allegedly failed to warn of risks
On Aug. 28 of last year Kimberley Yout, 45, was diagnosed with a rare brain infection that developed as a side effect of Tysabri, a drug she took for six years to keep her MS in check. Yout’s speech became slurred, her gait unsteady, and her future uncertain. Now, she is suing the two companies that marketed Tysabri — Biogen Idec Inc. of Weston and the Irish drug maker Elan Pharmaceuticals Inc.
The lawsuit is one of at least a half-dozen pending in Massachusetts and federal courts in three other states. In each case, plaintiffs are seeking more than $1 million in punitive damages from Biogen Idec and Elan on behalf of patients or their families. After taking Tysabri, the patients developed progressive multifocal leukoencephalopathy, known as PML, an infection of the brain’s white matter that can cause death or severe disability. Her complaint, filed Friday, alleges they failed to adequately warn patients of the risks some face from prolonged use of Tysabri.more



Shelley Peterman Schwarz: Secrets of a positive attitude!

Sylvi MacCormac credits her diagnosis with multiple sclerosis in 1982 at the age of 21 for her decision to create music full-time. 

Dispelling the misconceptions about multiple sclerosis

Cognitive functions in multiple sclerosis: impact of gray matter integrity   

Evaluation of circulating osteopontin levels in an unselected cohort of

Increased remissions in multiple sclerosis (MS) during late pregnancy may result from high levels of sex steroids such as estrogen and estriol. Estrogen (E2=17β-estradiol) protects against experimental autoimmune encephalomyelitis (EAE), but the cellular basis for E2-induced protection remains unclear.

Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.

Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).

Three men are raising money for the Multiple Sclerosis Society by attempting to walk the length of Hadrian's Wall.

The Bike MS: FedEx Rock-n-Roll Ride 2013 bike ride is in its fourth year in DeSoto County. The ride to end Multiple Sclerosis will be leaving the Landers Center ...

Chesapeake Challenge Walk raises money for MS research

Katy's muddy run for MS: Katy Hackling is gearing up to battle through thick mud, swim through lakes and run across challenging woodland to raise money for the Multiple Sclerosis Society.


Screening Mammo: Earlier is Better in Younger Women
More than two-thirds of breast cancer deaths occurred in younger women with no history of mammography or with intervals of 2 years or more between mammograms, a study of 7,300 breast cancer patients showed. More than two-thirds of breast cancer deaths occurred in younger women with no history of mammography or with intervals of 2 years or more between mammograms. The findings support initiation of mammographic screening before age 50.


Attributions and self-efficacy for physical activity in multiple sclerosis.
Self-efficacy is an important predictor of health-related physical activity in multiple sclerosis (MS). While past experiences are believed to influence efficacy beliefs, the explanations individuals provide for these experiences also may be critical.

Second line use of Fingolimod is as effective as (Tysabri) Natalizumab in a German out-patient RRMS-cohort.
Although Fingolimod is registered as a second-line drug in relapsing-remittend multiple sclerosis (RRMS) in Europe there are no clinical studies available comparing Fingolimod (FTY) and Natalizumab (N).

Which is the goal of cognitive rehabilitation in multiple sclerosis: the improvement of cognitive performance or the perception of cognitive deficits?

Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis

Protein array-based profiling of CSF identifies RBPJ as an autoantigen in
multiple sclerosis

Hunting for autoantibodies in multiple sclerosis

Neuroborreliosis during natalizumab treatment in multiple sclerosis

Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II)

Increased remissions in multiple sclerosis (MS) during late pregnancy may result from high levels of sex steroids such as estrogen and estriol.

Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
To investigate whether early binding antibody (BAb) titers or different IFN-b biomarkers predict NAb evolution.  BAb titers reliably predict NAbs. CXCL-10 is a promising sensitive biomarker for IFN-b response and its abrogation by anti-IFN-b antibodies.

Influence of multiple sclerosis, age and degree of disability, in the position of the contrast sensitivity curve peak.

A polymorphism in the resistin gene promoter and the risk of multiple sclerosis.

The Evaluation of the Retinal Nerve Fiber Layer in Multiple Sclerosis with Special-Domain Optical Coherence Tomography.

Y-39983, a Selective Rho-Kinase Inhibitor, Attenuates Experimental Autoimmune Encephalomyelitis via Inhibition of Demyelination.

Nuclear factor kappa B (NF-κB) in multiple sclerosis pathology.

Discovery of peptoid ligands for anti-aquaporin 4 antibodies.



Cigarette smoking and associated risk of multiple sclerosis

Exposure to cigarette smoke is emerging as an environmental risk factor for multiple sclerosis (MS). We investigated the possible association between environmental tobacco smoke, its cumulative exposure, and MS risk.

Our results demonstrate that cigarette smoking is significantly associated with an increased risk for MS. The risk effects of smoking were more noticeable in male patients and at higher tobacco doses.


Quality of life and employment in persons with multiple sclerosis.
In the current study, in an effort to examine the effects of type of employment upon quality of life (QOL), employment was divided into three categories (full-time employment, part-time employment, and unemployment).  Results of the study emphasize the need for the provision of quality vocational services to persons with MS. Issues such as quality vocational services, timeliness, and the importance of continued work are discussed.

The experience of being grounded: a phenomenological study of living with a wheelchair.
The purpose of this existential-phenomenological study was to investigate the experience of being in a wheelchair. It was a prelude to a pilot study examining the effect of "seated" Tai Chi.  The accommodations from the ADA Act have greatly facilitated the independence for those who are disabled, yet many obstacles remain.
on.

Monoclonal Antibodies in Treatment of Multiple Sclerosis.

Post-Tysabri (natalizumab) clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up.

No Differences Observed among Multiple Clinical S1P1 Receptor Agonists (Functional Antagonists) in S1P1 Receptor Down-regulation and Degradation.

Matrix metalloproteinases and their pathological upregulation in multiple sclerosis: an overview.

Standing Data Disproves Biomechanical Mechanism for Balance-Based Torso-Weighting.

Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?

Evolution of longitudinally extensive transverse myelitis in an aquaporin-4 IgG-positive patient.

[Genetic impairments of Wnt signaling pathways in hereditary high bone mass syndrome and sclerostosis diseases].

Steroid-responsive hearing impairment in NMO-IgG/aquaporin-4-antibody-positive neuromyelitis optica.

Connexin 43 astrocytopathy linked to rapidly progressive multiple sclerosis and neuromyelitis optica.

PRISM: A Novel Research Tool to Assess the Prevalence of Pseudobulbar Affect Symptoms across Neurological Conditions.

Higher Relative Risk for Multiple Sclerosis in a Pediatric and Adolescent Diabetes Population: Analysis From DPV Data Base.

Mesenchymal stromal-cell transplants induce oligodendrocyte progenitor migration and remyelination in a chronic demyelination model.

Giant pilomatricoma in a patient with tuberous sclerosis, both diagnosed in the adult life.

On the estimation and correction of bias in local atrophy estimations using example atrophy simulations

Distribution and expression of fibroblast-specific protein chemokine CCL21 and chemokine receptor CCR7 in renal allografts.

Increased plasma interleukin-32 expression in patients with neuromyelitis optica.



 1. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
Oral laquinimod may reduce (at least in the initial phase of treatment) some of the more destructive pathological processes in RRMS patients.

2. 2nd International Symposium on Gait and Balance in Multiple Sclerosis: interventions for gait and balance in MS.
Department of Physical Medicine and Rehabilitation, Kennedy Krieger Institute, Johns Hopkins University School of Medicine , Baltimore, MD , USA .

3. Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration.

4. Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders.

5. Disease-association analysis of an inflammation-related feedback loop.

6. Electrodiagnostic evaluation of peripheral nervous system changes in patients with multiple sclerosis.

7. Prevalence of neurological disorders in Al Quseir, Egypt: methodological aspects.

8. Longitudinally extensive varicella-zoster virus myelitis in a multiple sclerosis patient.

9. Alpha-B-crystallin induces an immune-regulatory and antiviral microglial response in preactive multiple sclerosis lesions.

10. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) in humans with multiple sclerosis.

11. Muscle-specific kinase antibody positive myaesthenia gravis and multiple sclerosis co-presentation: A case report and literature review.

12. A patient's perspective of partnership in the treatment of multiple sclerosis: MS regimes-An orchestrated approach.

13. Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration.

14. 2nd International Symposium on Gait and Balance in Multiple Sclerosis: interventions for gait and balance in MS.

15. Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders.

16. Autoantibodies to Potassium Channel KIR4.1 in Multiple Sclerosis.

17. Pediatric Inflammatory Diseases. Part IV: Miscellaneous, Reye, PRES, Sarcoidosis.

18. Pediatric inflammatory diseases. Part I: multiple sclerosis.

19. Practical Aspects of Shortening Acquisition Time in Brain MR Susceptibility-Weighted Imaging.

20. β-Arrestins 1 and 2 are critical regulators of inflammation.

21. BIOGEN HAS 3 NEW MS TREATMENTS THEY ARE WORKING ON THAT ARE BEING PRESENTED AT THE WORLDWIDE MEETING OF NEUROLOGISTS: ECTRIMS

22. VIDEO GAME HELPS EASE SYMPTOMS OF MS! PLUS: MSers CAN ENROLL IN UNIVERSITY'S STUDY

READ 109 MORE STUDIES & STORIES BY CLICKING ON "Read More" BELOW:

23. "First Direct Measurement of Spinal Cord Myelin in Multiple Sclerosis"

24. MS News Channel Expert Neurologist: Brian R. Apatoff, MD, PhD: MULTIPLE SCLEROSIS AND PAIN

27. A telerehabilitation program by virtual reality-video games improves balance and postural control in multiple sclerosis patients.
We suggest that our virtual reality program enables anticipatory PC and response mechanisms and might serve as a successful therapeutic alternative in situations in which conventional therapy is not readily available.


31. Carboxypeptidase N-deficient mice present with polymorphic disease phenotypes on induction of experimental autoimmune encephalomyelitis.
Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.:

32. Structure-Kinetics Relationships - an overlooked parameter in hit-to-lead optimization: a case of cyclopentylamines as CCR2 antagonists.

33. Parental illness, attachment dimensions, and health beliefs: testing the cognitive-behavioural and interpersonal models of health anxiety.

37. New hope for multiple sclerosis sufferer Lucy
dailyecho.co.uk

58. "Sometimes I find myself thinking pretty negative thoughts about my multiple sclerosis and I notice that my symptoms are worse"

59. "What is MS? Could You Have MS? 16 Multiple Sclerosis Symptoms (SLIDESHOW)"

60. 4 ways to manage double vision: Solutions to help manage this common symptom of MS

61. Terri Spats, Columnist & News Editor: MY COLUMN TODAY IS A MESSAGE TO THOSE WITH NO INVISIBLE ILLNESS

62. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort
Multiple Sclerosis Journal. 2013;  19(11): p. 1533-1538

63.  Teriflunomide for the treatment of multiple sclerosis.Oh J, O'Connor PW. Semin Neurol. 2013 Jul;33(3):307-8. doi: 10.1055/s-0033-1354604. Epub 2013 Sep 21.

64.  Endurance training is feasible in severely disabled patients with progressive multiple sclerosis. Skjerbæk A, Næsby M, Lützen K, Møller A, Jensen E, Lamers I, Stenager E, Dalgas U.
Mult Scler. 2013 Sep 20.

65. The relationship of cognitive impairment with neurological and psychiatric variables in multiple sclerosis patients.Karadayi H, Arisoy O, Altunrende B, Boztas HM, Sercan M.
Int J Psychiatry Clin Pract. 2013 Sep 19. [Epub ahead of print]

66. Altered likelihood of brain activation in attention and working memory networks in patients with multiple sclerosis: An ALE meta-analysis. Kollndorfer K, Krajnik J, Woitek R, Freiherr J, Prayer D, Schöpf V. Neurosci Biobehav Rev. 2013 Sep 18.

67. Circulating dendritic cells of multiple sclerosis patients are proinflammatory and their frequency is correlated with MS-associated genetic risk factors. Thewissen K, Nuyts AH, Deckx N, Wijmeersch BV, Nagels G, D'hooghe M, Willekens B, Cras P, Eijnde BO, Goossens H, Van Tendeloo VF, Stinissen P, Berneman ZN, Hellings N, Cools N. Mult Scler. 2013 Sep 20.

68. Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project plan. Rudick RA, Larocca N, Hudson LD; MSOAC. Mult Scler. 2013 Sep 20. [Epub ahead of print]

69. Outcomes after Microvascular Decompression for Patients with Trigeminal Neuralgia and Suspected Multiple Sclerosis.Ariai MS, Mallory GW, Pollock BE. World Neurosurg. 2013 Sep 19.

70. Risk factors related to cardiovascular diseases and the metabolic syndrome in multiple sclerosis - a systematic review. Wens I, Dalgas U, Stenager E, Eijnde BO.
Mult Scler. 2013 Sep 18. [Epub ahead of print]

71.Incidence and prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General Practice Research Database .Mackenzie IS, Morant SV, Bloomfield GA, Macdonald TM, O'Riordan J. J Neurol Neurosurg Psychiatry. 2013 Sep 19

72. Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients
Multiple Sclerosis Journal. 2013;  19(11): p. 1478-1484

73. What Is the JC Virus?

74. Royal recognition for Sussex Multiple Sclerosis Treatment Centre work
theargus.co

76. Newport man with multiple sclerosis to walk 60km
southwalesargus.co

79. MS may originate in brain's grey matter
netdoctor.co

81. STING may take the bite out of autoimmune diseases like multiple sclerosis, arthritis, Type 1 diabetes
brightsurf.com


84. Cowen: Half of new MS patients may soon get Biogen’s Tecfidera
bizjournals.com

85. "STING may take the bite out of autoimmune diseases"

86. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
In Assessment of OraL Laquinimod in PrEventing ProGRession in Multiple SclerOsis (ALLEGRO), a phase III study in relapsing-remitting multiple sclerosis (RRMS), oral laquinimod slowed disability and brain atrophy progression, suggesting laquinimod may reduce tissue damage in MS. MRI techniques sensitive to the most destructive aspects of the disease were used to further investigate laquinimod's potential effects on inflammation and neurodegeneration. Oral laquinimod may reduce (at least in the initial phase of treatment) some of the more destructive pathological processes in RRMS patients.

87. A 10-year follow-up of a population-based study of people with multiple sclerosis in Stockholm, Sweden: Changes in disability and the value of different factors in predicting disability and mortality.
The aims of this study were to evaluate changes in disability over ten years in PwMS, and to explore the value of personal and disease-specific factors and depressive symptoms in predicting disability. A further aim was to explore the value of these factors as predictors of mortality.This study illustrates the importance of tailored interventions for PwMS and highlights the need for health-care professionals to consider the psychological aspects of the disease. Furthermore, our results indicate that the Expanded Disability Status Scale was a useful tool for predicting future disability.

88. The B1-cell subpopulation is diminished in patients with relapsing-remitting multiple sclerosis.

89. Oxidative modification of serum proteins in multiple sclerosis.

90. Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).

   J Child Neurol. published 23 September 2013, 10.1177/0883073813501873

96. "Why do some people experience aggressive worsening of their multiple sclerosis and others experience a mild course?"

silive.com


100. Girl Swims to to Reach Fundraising
montereyherald.com


102. Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis
bionity.com


104. Swimming for a Cause: Scotts Valley youngster raises awareness, money for MS Association
insidebayarea.com


107. Manes & Motions: An Equine Assist For Special Needs 
courant.com

108. Trekking Hadrian’s Wall for Multiple Sclerosis Society





115. Psychological and physical predictors of illness intrusiveness in patients with multiple sclerosis.
Ferkauf Graduate School of Psychology, Yeshiva University, United States; Multiple Sclerosis Center of Holy Name Medical Center, United States.: Snyder S, Foley FW, Farrell E, Beier M, Zemon V.
J Neurol Sci. 2013 Sep 15;332(1-2):41-4. doi: 10.1016/j.jns.2013.06.009. Epub 2013 Jul 10.

116. Reduced grey matter perfusion without volume loss in early relapsing-remitting multiple sclerosis.
New Zealand Brain Research Institute, , Christchurch, New Zealand.: Debernard L, Melzer TR, Van Stockum S, Graham C, Wheeler-Kingshott CA, Dalrymple-Alford JC, Miller DH, Mason DF. J Neurol Neurosurg Psychiatry. 2013 Sep 13.
Grey matter (GM) pathology in multiple sclerosis (MS) is associated with progressive long-term disability. Detection of GM abnormalities in early MS may therefore be valuable in understanding and predicting the long-term course. However, structural MRI measures such as volume loss have shown only modest abnormalities in early relapsing-remitting MS (RRMS). We therefore investigated for evidence of abnormality in GM perfusion, consistent with metabolic dysfunction, in early RRMS.
The decrease in GM perfusion in the absence of volume loss is consistent with neuronal metabolic dysfunction in early RRMS. Future studies in larger cohorts and longitudinal follow-up are needed to investigate the functional and prognostic significance of the early GM perfusion deficits observed.

117. Bipolar disorder and multiple sclerosis: A case series.
Department of Neurology, Razi Hospital, Mannouba, Tunis, Tunisia.: Sidhom Y, Djebara MB, Hizem Y, Abdelkefi I, Kacem I, Gargouri A, Gouider R.
Behav Neurol. 2013 Sep 12. [Epub ahead of print]

118. Delayed Recovery of Leg Fatigue Symptoms Following a Maximal Exercise Session in People With Multiple Sclerosis.
1Oxford Brookes University, Oxford, UK.: Dawes H, Collett J, Meaney A, Duda J, Sackley C, Wade D, Barker K, Izadi H.
Neurorehabil Neural Repair. 2013 Sep 11.
Symptoms of fatigue were investigated during and following a single exercise session.
Monitoring leg fatigue symptoms during and through recovery from physical activities may help guide participation in physical activities for PwMS, particularly in people managing high levels of fatigue.

119. Exacerbation of experimental autoimmune encephalomyelitis by passive transfer of IgG antibodies from a multiple sclerosis patient responsive to immunoadsorption.
Neuroimmunology and Neuromuscular Disorders Unit, Foundation IRCCS Neurological Institute C. Besta, Via Celoria 11, 20133 Milan, Italy. Electronic address: rpedotti@istituto-besta.it.: Pedotti R, Musio S, Scabeni S, Farina C, Poliani PL, Colombo E, Costanza M, Berzi A, Castellucci F, Ciusani E, Confalonieri P, Hemmer B, Mantegazza R, Antozzi C.
J Neuroimmunol. 2013 Sep 15;262(1-2):19-26. 

120. Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.
 Cladribine causes sustained reduction in peripheral T and B cell populations while sparing other immune cells. We determined two populations of dendritic cells (DCs): namely CD1c(+)/CD19(-) (myeloid DCs) and CD303(+)/CD123(+) (plasmacytoid DCs), CD19(+) B lymphocytes, CD3(+) T lymphocytes and CD4(+) or CD8(+) subpopulations in patients with multiple sclerosis after cladribine therapy.
We noticed significant trend to increase the CD303(+) circulating the dendritic cells. This population produces large amounts of IFN-alfa. We found significant and rapid decrease in B cells and CD4(+) Th cells. Our results suggest two possible ways of beneficial cladribine influence on immune system in MS. Induction of IFN-alfa producing cells and their predominance over BDCA-1(+) DCs, which are associated with cytotoxic response. Additionally, cladribine could influence two populations of lymphocytes: B cells and Th lymphocytes responsible for induction of immune response against myelin antigens.

121. Intrathecal oligoclonal IgG synthesis in multiple sclerosis.
Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands; UCL Institute of Neurology, Neuroimmunology & CSF Laboratory, Queen Square, London, United Kingdom. Electronic address: a.petzold@vumc.nl.: J Neuroimmunol. 2013 Sep 15;262(1-2):1-10

   Inez Wens, Ulrik Dalgas, Egon Stenager, and Bert O. Eijnde
   Multiple Sclerosis Journal. published 18 September 2013


123. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort
131. CCSVI TERRIBLE NEWS! CANADIAN RESEARCHERS FAILED TO FIND ANY VEIN BLOCKAGES IN 99 OF 100 PATIENTS

132. Place of death, and its relation with underlying cause of death, in Parkinson’s disease, motor neurone disease, and multiple sclerosis: A population-based study Little is known about place of death 

Wall Street Journal 
134. UCSF Researcher First Winner of Prize for Innovative Work on Multiple Sclerosis
UCSF News Services
137. Place of death, and its relation with underlying cause of death, in Parkinson’s disease, motor neurone disease, and multiple sclerosis: A population-based study 
Little is known about place of death in chronic neurological diseases. Mortality statistics are ideal for examining trends in place of death, but analyses are limited by coding rule changes.  Underlying cause of death has a marked effect on place of death. The effects of coding rule changes are an essential consideration for all research using underlying cause of death to study place of death.

 144. MS Walk connects people, raises fundsKilleen Daily Herald
145. A telerehabilitation program by virtual reality-video games improves balance and postural control in multiple sclerosis patients.
Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Faculty of Health Sciences, ReyJuanCarlosUniversity, Alcorcón, Madrid, Spain.: Gutiérrez RO, Galán Del Río F, Cano de la Cuerda R, Alguacil Diego IM, González RA, Page JC.
To demonstrate the potential improvements in balance and PC among patients with MS who complete a virtual reality telerehabilitation program that represents a feasible alternative to physical therapy for situations in which conventional treatment is not available.
We suggest that our virtual reality program enables anticipatory PC and response mechanisms and might serve as a successful therapeutic alternative in situations in which conventional therapy is not readily available.

146. Carboxypeptidase N-deficient mice present with polymorphic disease phenotypes on induction of experimental autoimmune encephalomyelitis.
Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.: Hu X, Wetsel RA, Ramos TN, Mueller-Ortiz SL, Schoeb TR, Barnum SR.



JOSI CREEK, GUEST COLUMNIST: "They took my morphine cold turkey from me because i don't act normal they thought i was a drug abuser

Patti McArthur, Columnist: MY PAIN DOC FIRED ME & SENT ME BACK TO MY MS DOCTOR WHO GAVE ME SHOTOS OF BOTOX IN MY SKULL TO HELP THE MIGRAINES!

The American Academy of Neurology's Top Five Choosing Wisely recommendations
DeAnn Burgess, Lemtrada Editor: MY LEMTRADA DIARY: I saw my neuro today & he tested me! I actually had knee reflexes!!!!!!!!!!!!!

Meg Jones, Columnist: MY COLUMN THIS WEEK IS ABOUT PERSEVERANCE]" WILL GIVE YOU GOOD TEARS & HOPE FOR THE FUTURE!

Valorie Diamond, Columnist: PAIN...LIVE OR LET RULE   


FRIENDS & FAMILY DON'T UNDERSTAND YOUR MS? SHARE THIS ARTICLE WITH THEM: IT WILL MAKE THEM UNDERSTAND: "The Physiological Changes of MS"

STRESS IS NOT MS'S FRIEND! 20 Scientifically-Backed Ways To De-Stress Right Now

EDUCATIONAL ACTIVITY FOR: neurologists, neurology nurses, pharmacists and other healthcare professionals involved in the treatment of patients with multiple sclerosis.

KATRINA ANN TAYLOR, COLUMNIST: I WON'T GIVE UP ON MYSELF AFTER MY HEART BREAK & LOSS

Beth Dean, News Editor & Columnist: I'M PROUD TO SAY I'M A COPAXONE GIRL
Multiple Sclerosis Appears to Originate in Different Part of Brain Than Long Believed

Biogen Idec, Elan facing suits over Tysabri PML side effects! Biogen allegedly failed to warn Multiple Sclerosis patients of risks

FOR DOCTORS ONLY: Charting Progress in MS Treatment: Initiating, Monitoring, and Switching Disease-Modifying Therapy

Kerry Galcik, Columnist, MSnewsChannel.com: THIS IS MY 1ST COLUMN! I look forward to writing as a new columnist!


 Sexual dysfunction has a much larger detrimental impact on mental health than severity of MS physical disability.

Yvonne Decelis, Columnist: MY TECFIDERA DIARY: MY MEMORY & PAIN PROBLEMS ARE DISAPPEARING

LAUREN PARROTT IS OUR NEWEST COLUMNIST! In 2005, at the age of 21, Lauren was an intern at Good Morning America & has over 100 videos on YouTube

GET YOUR FREE MAGAZINE NOW: The Rocky Mountain MS Center's Magazine is FREE for our readers! Click either of the 2 links below to read the Summer Issue of InforMS

PAIN Week 2013: Proposed Opioid Reduction Guideline Reduces Depression, Pain

PAIN Week 2013:FDA Restricts Long-term Opioid Use to Combat Abuse

PAIN Week 2013: Five-Step Plan Helps Patients Cope With Pain

CINDI HOPPER, COLUMNIST: One of the worst things we have to face having MS is those days when our balance is not quite right

The FDA ordered label changes for long-acting and extended-release opioids such as OxyContin, limiting approved use to severe pain that cannot be relieved with other treatments

Valorie Diamond, Columnist: MY COLUMN THIS WEEK INCLUDES A FEW TIPS THAT HELP ME DEAL WITH MS

LOTS OF MSers NEED HELP WITH COGNITION: VIDEO GAME TRAINING CAN BOOST COGNITION

April Barbosa, Columnist & Poet: MEDICAL MARIJUANA GAVE ME MY LIFE BACK BY HELPING ME BATTLE THE MS MONSTER

PAIN Week 2013: Proposed Opioid Reduction Guideline Reduces Depression, Pain

Labels: Aubagio, Gilenya, Lemtrada, Novantrone, TECFIDERA, Tysabri